Search results

395 results

Sorted by Date . Sort by Relevance

  1. Type 2 diabetes: alogliptin (ESNM20)

    Summary of the evidence on alogliptin (a dipeptidyl peptidase-4 [DPP-4] inhibitor) for type 2 diabetes to inform local NHS planning and decision-making

  2. Schizophrenia: lurasidone (ESNM48)

    Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

  3. Erectile dysfunction: avanafil (ESNM45)

    Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

  4. Scleroderma: oral mycophenolate (ESUOM32)

    Summary of the evidence on oral mycophenolate for systemic sclerosis (scleroderma) to inform local NHS planning and decision-making

  5. Chronic pain: oral ketamine (ESUOM27)

    Summary of the evidence on oral ketamine for treating chronic pain to inform local NHS planning and decision-making

  6. Pouchitis: rifaximin (ESUOM30)

    Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making